Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marbox… Read more
Traws Pharma Inc (TRAW) - Net Assets
Latest net assets as of September 2025: $4.54 Million USD
Based on the latest financial reports, Traws Pharma Inc (TRAW) has net assets worth $4.54 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.44 Million) and total liabilities ($7.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.54 Million |
| % of Total Assets | 36.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | -612.23% |
| 10-Year Change | -391.79% |
| Growth Volatility | 263.99 |
Traws Pharma Inc - Net Assets Trend (2011–2024)
This chart illustrates how Traws Pharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Traws Pharma Inc (2011–2024)
The table below shows the annual net assets of Traws Pharma Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-31.63 Million | -396.38% |
| 2023-12-31 | $10.67 Million | -62.30% |
| 2022-12-31 | $28.31 Million | -38.62% |
| 2021-12-31 | $46.12 Million | +646.88% |
| 2020-12-31 | $6.17 Million | -46.65% |
| 2019-12-31 | $11.57 Million | +114.85% |
| 2018-12-31 | $5.39 Million | +149.60% |
| 2017-12-31 | $-10.86 Million | -311.84% |
| 2016-12-31 | $5.13 Million | -52.70% |
| 2015-12-31 | $10.84 Million | -54.11% |
| 2014-12-31 | $23.62 Million | -70.80% |
| 2013-12-31 | $80.90 Million | +151.10% |
| 2012-12-31 | $-158.31 Million | -14.37% |
| 2011-12-31 | $-138.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Traws Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 51071300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $36.00K | % |
| Other Comprehensive Income | $-42.00K | % |
| Other Components | $617.53 Million | % |
| Total Equity | $-31.63 Million | 100.00% |
Traws Pharma Inc Competitors by Market Cap
The table below lists competitors of Traws Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Galena Mining Ltd
AU:G1A
|
$12.14 Million |
|
The INX Digital Company Inc.
OTCQB:INXDF
|
$12.15 Million |
|
CryoCell International Inc
NYSE MKT:CCEL
|
$12.15 Million |
|
Medicus Pharma Ltd. Common Stock
OTCBB:MDCX
|
$12.15 Million |
|
New Tech Minerals Corp
OTCQB:APCOF
|
$12.13 Million |
|
Can One Bhd
KLSE:5105
|
$12.13 Million |
|
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ:CVKD
|
$12.13 Million |
|
Town Center Bank
OTCQX:TCNB
|
$12.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Traws Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,672,000 to -31,630,000, a change of -42,302,000 (-396.4%).
- Net loss of 54,674,000 reduced equity.
- New share issuances of 33,976,000 increased equity.
- Other comprehensive income decreased equity by 19,000.
- Other factors decreased equity by 21,585,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-54.67 Million | -172.85% |
| Share Issuances | $33.98 Million | +107.42% |
| Other Comprehensive Income | $-19.00K | -0.06% |
| Other Changes | $-21.59 Million | -68.24% |
| Total Change | $- | -396.38% |
Book Value vs Market Value Analysis
This analysis compares Traws Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-614594.62 | $2.11 | x |
| 2012-12-31 | $-702894.95 | $2.11 | x |
| 2013-12-31 | $426956.57 | $2.11 | x |
| 2014-12-31 | $59093.39 | $2.11 | x |
| 2015-12-31 | $24761.29 | $2.11 | x |
| 2016-12-31 | $5460.25 | $2.11 | x |
| 2017-12-31 | $-7306.88 | $2.11 | x |
| 2018-12-31 | $489.86 | $2.11 | x |
| 2019-12-31 | $301.74 | $2.11 | x |
| 2020-12-31 | $13.31 | $2.11 | x |
| 2021-12-31 | $68.50 | $2.11 | x |
| 2022-12-31 | $33.85 | $2.11 | x |
| 2023-12-31 | $12.71 | $2.11 | x |
| 2024-12-31 | $-20.37 | $2.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Traws Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24192.04%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-165.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -2038.60% | 0.33x | 0.00x | $-16.47 Million |
| 2012 | 0.00% | -73.32% | 0.55x | 0.00x | $-18.03 Million |
| 2013 | -80.66% | -1364.67% | 0.05x | 1.31x | $-72.90 Million |
| 2014 | -279.95% | -7960.25% | 0.02x | 2.08x | $-65.96 Million |
| 2015 | -239.55% | -209.31% | 0.49x | 2.34x | $-24.98 Million |
| 2016 | -457.69% | -354.62% | 0.24x | 5.41x | $-20.10 Million |
| 2017 | 0.00% | -3061.25% | 0.16x | 0.00x | $-22.92 Million |
| 2018 | -381.90% | -1675.33% | 0.07x | 3.33x | $-21.11 Million |
| 2019 | -185.79% | -985.02% | 0.09x | 2.05x | $-22.66 Million |
| 2020 | -407.40% | -10890.48% | 0.01x | 3.24x | $-25.77 Million |
| 2021 | -35.05% | -7151.77% | 0.00x | 1.20x | $-20.77 Million |
| 2022 | -66.99% | -8391.15% | 0.01x | 1.39x | $-21.79 Million |
| 2023 | -177.55% | -8384.07% | 0.01x | 2.13x | $-20.02 Million |
| 2024 | 0.00% | -24192.04% | 0.01x | 0.00x | $-51.51 Million |
Industry Comparison
This section compares Traws Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Traws Pharma Inc (TRAW) | $4.54 Million | 0.00% | 1.74x | $12.14 Million |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |